New regn5458 (bcmaxcd3) phase 1 data show 75% response rate at highest dose levels studied in patients with heavily pretreated multiple myeloma

Tarrytown, n.y., dec. 11, 2021 /prnewswire/ --  includes latest data for regn5458, including in highest dose levels (200-800 mg) among patients who responded across all dose groups (3-800 mg), there was a 90% probability of being event-free (i.e.
REGN Ratings Summary
REGN Quant Ranking